Surveillance systems overview for 2017
- Chikungunya virus disease
- Chlamydia infection
- Crimean-Congo haemorrhagic fever
- Ebola haemorrhagic fever
- Hantavirus infection
- Healthcare-associated infections
- Hepatitis A
- Hepatitis B
- Hepatitis C
- HIV infection
- Invasive Haemophilus influenzae disease
- Lassa fever
- Marburg haemorrhagic fever
- Meningococcal disease
- Pneumococcal disease
- Q fever
- Rift Valley fever
- Severe acute respiratory syndrome (SARS)
- Surgical site infections
- Verotoxigenic Escherichia coli infection
- West Nile virus infection
- Yellow fever
Reaching the SDG targets on Health by 2030: ECDC Session at European Health Forum Gastein 2018
Will we reach the United Nations Sustainable Development Goal (SDG) for health by 2030 and the targets set for HIV/AIDS, hepatitis and tuberculosis?
Public health guidance on prevention and control of blood-borne viruses in prison settings
This document provides EU/EEA Member States with evidence-based scientific advice on available options, when planning and implementing prevention and control interventions for blood-borne viruses in prison settings.
Preventing blood-borne viruses in prison settings: ECDC and EMCDDA Guidance
People in prison experience a higher burden of communicable diseases such as hepatitis B (HBV), hepatitis C (HCV) and HIV often linked to a history of injecting drug use.
Guidance in brief: Prevention and control of blood-borne viruses in prison settings
This guidance is intended for policymakers responsible for the planning and delivery of healthcare services in the national or sub-national custodial system and all professionals responsible for the health and well-being of people in prison, including community-based service providers and those facilitating continuity of care in the community.
Systematic review on the prevention and control of blood-borne viruses in prison settings
The objective of this report was to systematically review data on prevention and control of BBVs in prison settings, with a focus on the countries of the European Union (EU) and the European Economic Area (EEA).
Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysis
Harausz, E.P., Garcia-Prats, A.J., Law, S., Schaaf, H.S., Kredo, T., Seddon, J.A., Menzies, D., Turkova, A., Achar, J., Amanullah, F., Barry, P., Becerra, M., Chan, E.D., Chan, P.C., Ioana Chiotan, D., Crossa, A., Drobac, P.C., Fairlie, L., Falzon, D., Flood, J., Gegia, M., Hicks, R.M., Isaakidis, P., Kadri, S.M., Kampmann, B., Madhi, S.A., Marais, E., Mariandyshev, A., Méndez-Echevarría, A., Moore, B.K., Nargiza, P., Ozere, I., Padayatchi, N., ur-Rehman, S., Rybak, N., Santiago-Garcia, B., Shah, N.S., Sharma, S., Shim, T.S., Skrahina, A., Soriano-Arandes, A., van den Boom, M., van der Werf, M.J., van der Werf, T.S., Williams, B., Yablokova, E., Yim, J.-J., Furin, J., Hesseling, A.C.
Public health guidance on active case finding of communicable diseases in prison settings
This joint guidance from ECDC and the European Monitoring Centre for Drugs and Drug Addiction provides EU/EEA Member States with evidence-based scientific advice on active case finding options. These options can be applied to the planning and implementation of interventions that promote the early diagnosis of communicable diseases in prison settings.
ECDC and EMCDDA make the case for active case finding of communicable diseases in prison
In their joint public health Guidance published today, ECDC and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), present the evidence on active case finding as a key measure to diagnose communicable diseases early.